Reason for request
Extension d'indication non sollicitée
Le laboratoire a informé la HAS de sa demande de non remboursement dans l’indication « IMFINZI est indiqué en monothérapie dans le traitement de première ligne des patients adultes atteints d'un carcinome hépatocellulaire (CHC) avancé ou non résécable ».
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
YgGCHg7PB5kuyLgL
